Afbouw strategieën bij door anti-TNF&MTX geïnduceerde remissie bij Reumatoïde Arthritis. Moeten we MTX of anti-TNF als eerste afbouwen?

TApering strategies in TNFi&MTX induced remission in Rheumatoid Arthritis. Should we taper MTX or TNFi first?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21808

Enrollment

355

Registered

2011-02-14

Start date

2011-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Randomization into two arms: 1. Tapering the csDMARD first, then the TNF-inhibitor

2. Tapering the TNF-inhibitor first, then the csDMARD.

Eligibility

Inclusion criteria

Inclusion criteria: 1. RA patients; 2. Aged >17 years; 3. Treated with a csDMARD & TNF-inhibitor; 4. DAS44 <= 2.4 & SJC<=1 for two consecutive time points (3 months).

Exclusion criteria

Exclusion criteria: 1. Not being able to understand, speak and write in Dutch; 2. Being diagnosed with a psychiatric or personality disorder.

Design outcomes

Primary

Measure	Time frame
1. Number of flares in each arm; 2. Incremental Cost Effectiveness Ratio (ICER) of one strategy over the other.	—

Secondary

Measure	Time frame
1. Radiographic progression after 1 and 2 years; 2. HAQ, the SF36, sick leave, productivity loss at work and cost-effectiveness modelled over the long term.	—

Contacts

Public ContactE. van Mulligen

Postbus 2040

elise.vanmulligen@erasmusmc.nl+31650032371

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)